ライフサイエンスコーパス: glucagon-like peptide

1 w focuses on two peptide drugs - insulin and glucagon-like peptide 1 (GLP-1) - for treatment of type

2 fy 37 T2D patients who were actively using a Glucagon-like peptide 1 (GLP-1) agonist in addition to a

3 Glucagon-like peptide 1 (GLP-1) agonists have shown card

4 Glucagon-like peptide 1 (GLP-1) also has insulin-indepen

5 The glucagon-like peptide 1 (GLP-1) analog, liraglutide, is

6 Exendin-4 is a long acting glucagon-like peptide 1 (GLP-1) analogue that is an agon

7 ipeptidyl peptidase 4 (DPP-4) inhibitors and glucagon-like peptide 1 (GLP-1) analogues, can increase

8 Dual activation of the glucagon-like peptide 1 (GLP-1) and glucagon receptor ha

9 peptide possessing balanced coagonism at the glucagon-like peptide 1 (GLP-1) and glucagon receptors c

10 In contrast, AR231453 increased plasma glucagon-like peptide 1 (GLP-1) and insulin levels and i

11 Acute administration of glucagon-like peptide 1 (GLP-1) and its agonists slows g

12 sized that enteroendocrine L-cells producing glucagon-like peptide 1 (GLP-1) and peptide YY (PYY) may

13 ssed on enteroendocrine L cells that release glucagon-like peptide 1 (GLP-1) and peptide YY (PYY) whe

14 Glucagon-like peptide 1 (GLP-1) and serotonin play criti

15 nsulin increased by 120% +/- 15% (P = 0.02), glucagon-like peptide 1 (GLP-1) by 60% +/- 20% (P < 0.01

16 ecretion of the prosurvival incretin hormone glucagon-like peptide 1 (GLP-1) by alpha cells and acts

17 Exocytosis of the hormone glucagon-like peptide 1 (GLP-1) by the intestinal L cell

18 Since glucagon-like peptide 1 (GLP-1) exerts neuroprotective e

19 Therapeutic engineering of glucagon-like peptide 1 (GLP-1) has enabled development

20 Glucagon-like peptide 1 (GLP-1) immunoreactivity of plas

21 Glucagon-like peptide 1 (GLP-1) is a hormone with essent

22 The gut hormone called glucagon-like peptide 1 (GLP-1) is a strong moderator of

23 Glucagon-like peptide 1 (GLP-1) is secreted by intestina

24 The physiologic properties of glucagon-like peptide 1 (GLP-1) make it a potent candida

25 Moreover, ANP potentiated the effect of glucagon-like peptide 1 (GLP-1) on glucose-induced insul

26 The incretin hormone glucagon-like peptide 1 (GLP-1) promotes glucose homeost

27 The glucagon-like peptide 1 (GLP-1) receptor (GLP-1R) is a k

28 armacological activation of the hypothalamic glucagon-like peptide 1 (GLP-1) receptor (GLP-1R) promot

29 Glucagon-like peptide 1 (GLP-1) receptor agonists (GLP-1

30 Glucagon-like peptide 1 (GLP-1) receptor agonists induce

31 al models of type 2 diabetes have shown that glucagon-like peptide 1 (GLP-1) receptor agonists preven

32 e-18]fluoro-levodopa [(18)F-DOPA] PET-CT and glucagon-like peptide 1 (GLP-1) receptor imaging), and d

33 The glucagon-like peptide 1 (GLP-1) receptor is a class B G

34 Glucagon-like peptide 1 (GLP-1) reduces hyperglucagonemi

35 Glucagon-like peptide 1 (GLP-1) regulates glucose homeos

36 gon released from pancreatic alpha cells and glucagon-like peptide 1 (GLP-1) released from intestinal

37 The incretin hormone Glucagon-like peptide 1 (GLP-1) requires delivery by inj

38 Glucose is an important stimulus for glucagon-like peptide 1 (GLP-1) secretion, but the mecha

39 pendent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) secretion, on glucose lo

40 in from adipocytes and by those means induce glucagon-like peptide 1 (GLP-1) secretion.

41 enhancing the action of the incretin hormone glucagon-like peptide 1 (GLP-1) therapeutically improve

42 This study tested the hypothesis that glucagon-like peptide 1 (GLP-1) therapies improve cardia

43 The contribution of elevated glucagon-like peptide 1 (GLP-1) to postprandial glucose

44 In contrast, glucagon-like peptide 1 (GLP-1) was approximately 64% hi

45 proof-of-principle, the clinically relevant glucagon-like peptide 1 (GLP-1) was functionalized with

46 Glucagon-like peptide 1 (GLP-1) was substantially increa

47 Upon a nutrient challenge, L cells produce glucagon-like peptide 1 (GLP-1), a powerful stimulant of

48 ty acids (FFAs), insulin, glucose, glucagon, glucagon-like peptide 1 (GLP-1), and gastric inhibitory

49 in plasma cholecystokinin, peptide YY (PYY), glucagon-like peptide 1 (GLP-1), and glucagon-like pepti

50 poststimulation levels of glucose, insulin, glucagon-like peptide 1 (GLP-1), and glucose-dependent i

51 ) inhibitor that inhibits the degradation of glucagon-like peptide 1 (GLP-1), and has been approved f

52 kinin, gastric inhibitory polypeptide (GIP), glucagon-like peptide 1 (GLP-1), and peptide tyrosine ty

53 wn at regular intervals for cholecystokinin, glucagon-like peptide 1 (GLP-1), and peptide YY (PYY) an

54 been linked to the exaggerated secretion of glucagon-like peptide 1 (GLP-1), but causality has not b

55 elated to changes in blood peptide YY (PYY), glucagon-like peptide 1 (GLP-1), glucose, or insulin con

56 ing glucose, lipids (fasting only), insulin, glucagon-like peptide 1 (GLP-1), peptide YY (PYY), and g

57 Fasting and postprandial plasma glucagon-like peptide 1 (GLP-1), peptide YY (PYY), and g

58 RC1), general control nonrepressed 2 (GCN2), glucagon-like peptide 1 (GLP-1), peptide YY (PYY), serot

59 Glucagon-like peptide 1 (GLP-1), secreted from intestina

60 diabetes associated with the stimulation of glucagon-like peptide 1 (GLP-1), which is known to slow

61 erhans is enhanced by the intestinal hormone glucagon-like peptide 1 (GLP-1), which is secreted from

62 Glucagon-like Peptide 1 (GLP-1)-expressing neurons in th

63 S) in the circulation and thereby stimulates glucagon-like peptide 1 (GLP-1)-mediated insulin secreti

64 Here, we present evidence for glucagon-like peptide 1 (GLP-1)-mediated paraventricular

65 studies in subjects with diabetes receiving glucagon-like peptide 1 (GLP-1)-targeted therapies have

66 elease of the incretin and satiating peptide glucagon-like peptide 1 (GLP-1).

67 se of satiety-promoting gut hormones such as glucagon-like peptide 1 (GLP-1).

68 with increased secretion of the gut hormone glucagon-like peptide 1 (GLP-1).

69 increased postprandial levels of insulin and glucagon-like peptide 1 (GLP-1).

70 of either the accumulation or antagonism of glucagon-like peptide 1 (GLP-1).

71 stimulates secretion of the incretin hormone glucagon-like peptide 1 (GLP-1).

72 Consistent with this model, a glucagon-like peptide 1 (GLP1) agonist, which stimulates

73 We describe this method using dulaglutide, a glucagon-like peptide 1 (GLP1)-Fc fusion protein.

74 P = .003), and higher postprandial levels of glucagon-like peptide 1 (P < .001).

75 rs prevent degradation of incretin hormones (glucagon-like peptide 1 [GLP-1] and glucose-dependent in

76 The cardiovascular effects of semaglutide, a glucagon-like peptide 1 analogue with an extended half-l

77 The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard

78 ontrolled trial that compared liraglutide, a glucagon-like peptide 1 analogue, with placebo in patien

79 Levels of glucagon-like peptide 1 and gastric inhibitory polypepti

80 with PS-CF and normal control subjects, and glucagon-like peptide 1 and gastric inhibitory polypepti

81 improves glucose tolerance while stimulating glucagon-like peptide 1 and insulin secretion.

82 ed with lower glucose and ghrelin and higher glucagon-like peptide 1 and peptide tyrosine-tyrosine re

83 Mean changes in serum glucagon-like peptide 1 and peptide YY were 106.6% +/- 2

84 ther dose affected plasma ghrelin, glucagon, glucagon-like peptide 1 and peptide YY, or pyloric and d

85 g, enhanced postprandial cholecystokinin and glucagon-like peptide 1 concentrations, and reduced ghre

86 in human beta-cells, using forskolin or the glucagon-like peptide 1 mimetic Exendin-4, inhibits the

87 igher early postprandial cholecystokinin and glucagon-like peptide 1 peaks than did the other partici

88 ted depletion, which could not be rescued by glucagon-like peptide 1 pretreatment.

89 abetic C57BL/6J mice treated with either the glucagon-like peptide 1 receptor (GLP-1R) agonist liragl

90 Glucagon-like peptide 1 receptor (GLP-1R) agonists are i

91 like peptide-1 (GLP-1) signaling through the glucagon-like peptide 1 receptor (GLP-1R) is a key regul

92 Glucagon-like peptide 1 receptor (GLP-1R) signaling in t

93 und that exendin-4 (Ex-4), an agonist of the glucagon-like peptide 1 receptor (GLP-1R), stimulates hu

94 ron oxide-based nanoparticle probe targeting glucagon-like peptide 1 receptor (GLP-1R), which is high

95 Glucagon-like peptide 1 receptor (GLP1R) agonists are wi

96 The short-acting glucagon-like peptide 1 receptor agonist exenatide reduc

97 ctivities of NRTN relative to liraglutide, a glucagon-like peptide 1 receptor agonist, in Zucker diab

98 cagon was elevated, and cells expressing the glucagon-like peptide 1 receptor were more abundant in R

99 Glucagon-like peptide 1 receptors (GLP-1Rs) have been fo

100 In nonfasted rats, central antagonism of glucagon-like peptide 1 receptors partially mimics the e

101 urgery, beta-cell function, weight loss, and glucagon-like peptide 1 response were all predictors of

102 e/isoleucine, methionine, phenylalanine, and glucagon-like peptide 1 response were associated with ch

103 onses to acute stress by "silencing" central glucagon-like peptide 1 signaling pathways.

104 rease in alpha-cells containing glucagon and glucagon-like peptide 1 with HFS diets.

105 enome editing to controllably release GLP-1 (glucagon-like peptide 1), a critical incretin that regul

106 se-dependent insulinotropic polypeptide, and glucagon-like peptide 1), glucose, and multiple AAs, inc

107 y reports activation in response to insulin, glucagon-like peptide 1, and agents that raise cAMP leve

108 ve for either prolactin-releasing peptide or glucagon-like peptide 1, and attenuates the activation o

109 ut hormones, fibroblast growth factor 19 and glucagon-like peptide 1, and the BA transport systems, a

110 nsional ultrasound), plasma cholecystokinin, glucagon-like peptide 1, glucose-dependent insulinotropi

111 h plasma concentrations of acylated ghrelin, glucagon-like peptide 1, insulin, glucose, and nonesteri

112 l motility, plasma ghrelin, cholecystokinin, glucagon-like peptide 1, peptide YY, insulin, glucagon,

113 Glucagon-like peptide 1-based therapies, collectively de

114 tidyl-peptidase 4-inhibitor sitagliptin, the glucagon-like peptide 1-receptor agonist lixisenatide ba

115 We assessed the effects of lixisenatide, a glucagon-like peptide 1-receptor agonist, on cardiovascu

116 mentation of fibroblast growth factor 21 and glucagon-like peptide 1.

117 es of glucose, insulin, C-peptide, glucagon, glucagon-like peptides 1 and 2, gastric inhibitory pepti

118 Supplementation of FOS increased glucagon like peptide-1 content as well as Bifidobacteri

119 ulted in elevated C-peptide levels, elevated glucagon like peptide-1 levels and a reduction in dipept

120 A 72-hour continuous infusion of either glucagon-like peptide-1 (1.5 pmol/kg/min) or normal sali

121 Glucagon-like peptide-1 (7-36) amide is a safe and effic

122 The incretin glucagon-like peptide-1 (7-36) amide is both insulinotro

123 Endogenous glucagon-like peptide-1 (7-36) is augmented by pharmacol

124 Sitagliptin increased plasma glucagon-like peptide-1 (7-36) levels and, at peak stres

125 Potentiation of glucagon-like peptide-1 (GLP-1) action through selective

126 Liraglutide is a glucagon-like peptide-1 (GLP-1) analog marketed for the

127 Glucagon-like peptide-1 (GLP-1) analogs are approved for

128 dipeptidyl peptidase-4 (DPP4) inhibitors and glucagon-like peptide-1 (GLP-1) analogs, are important n

129 ed the efficacy and safety of semaglutide, a glucagon-like peptide-1 (GLP-1) analogue in clinical dev

130 Semaglutide is a glucagon-like peptide-1 (GLP-1) analogue in phase 3 deve

131 al insulin analogue insulin degludec and the glucagon-like peptide-1 (GLP-1) analogue liraglutide has

132 Liraglutide is an acylated glucagon-like peptide-1 (GLP-1) analogue that binds to s

133 Glucagon-like peptide-1 (GLP-1) analogues reduce hepatic

134 Glucagon-like peptide-1 (GLP-1) and cholecystokinin (CCK

135 ate the anorectic effects of both endogenous glucagon-like peptide-1 (GLP-1) and exogenous GLP-1 rece

136 creting glucagon, insulin, and the incretins glucagon-like peptide-1 (GLP-1) and GIP (glucose-depende

137 Incretin peptides (glucagon-like peptide-1 (GLP-1) and glucose-dependent in

138 esponses to glucose and to incretins such as glucagon-like peptide-1 (GLP-1) and glucose-dependent in

139 , Tukey's post hoc, P < 0.05]; and increased glucagon-like peptide-1 (GLP-1) and peptide YY (PYY) com

140 e of enteroendocrine L-cell derived hormones glucagon-like peptide-1 (GLP-1) and peptide YY (PYY) in

141 elease of gastrointestinal peptides, such as glucagon-like peptide-1 (GLP-1) and peptide YY (PYY), fr

142 circulating glucose, insulin, glucagon, and glucagon-like peptide-1 (GLP-1) concentrations and subje

143 d this increase is associated with increased glucagon-like peptide-1 (GLP-1) concentrations.

144 We have examined analogues of glucagon-like peptide-1 (GLP-1) containing beta-amino ac

145 red changes in cell health and intracellular glucagon-like peptide-1 (GLP-1) content.

146 Glucagon-like peptide-1 (GLP-1) controls glucose homeost

147 The peptide hormone glucagon-like peptide-1 (GLP-1) enhances glucose-induced

148 Multiple physiological properties of glucagon-like peptide-1 (GLP-1) ensure that it is a prom

149 In this study, we focused on the function of glucagon-like peptide-1 (GLP-1) in initial responses to

150 Pharmacological evidence suggests a role for glucagon-like peptide-1 (GLP-1) in modulating stress res

151 e acid synthesis and intestinal secretion of glucagon-like peptide-1 (GLP-1) in wild-type, Fxr(-/-),

152 Exogenous glucagon-like peptide-1 (GLP-1) inhibits eating in healt

153 Glucagon-like peptide-1 (GLP-1) is a hormone that stimul

154 Glucagon-like peptide-1 (GLP-1) is a natural agonist for

155 Glucagon-like peptide-1 (GLP-1) is an incretin that play

156 ic polypeptide (GIP) is glucagonotropic, and glucagon-like peptide-1 (GLP-1) is glucagonostatic.

157 Glucagon-like peptide-1 (GLP-1) is produced in the ileum

158 Glucagon-like peptide-1 (GLP-1) is produced in the small

159 The multiple physiological properties of glucagon-like peptide-1 (GLP-1) make it a promising drug

160 Since hindbrain glucagon-like peptide-1 (GLP-1) neurons and noradrenergi

161 Here we show that nicotine activates glucagon-like peptide-1 (GLP-1) neurons in the nucleus t

162 impaired; this impairment is ameliorated by glucagon-like peptide-1 (GLP-1) or by GLP-1 receptor ago

163 The BAS-BA complex also induces glucagon-like peptide-1 (GLP-1) production by L cells wh

164 Glucagon-like peptide-1 (GLP-1) receptor (GLP-1R) agonis

165 Glucagon-like peptide-1 (GLP-1) receptor (GLP-1R), gluca

166 Exendin-4, a glucagon-like peptide-1 (GLP-1) receptor agonist adminis

167 We have generated a humanized glucagon-like peptide-1 (GLP-1) receptor agonist antibod

168 Exendin-4 (EX-4), a glucagon-like peptide-1 (GLP-1) receptor agonist, has be

169 Exenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has ne

170 table therapy, clinicians can choose between glucagon-like peptide-1 (GLP-1) receptor agonists and ba

171 New drugs for the treatment of diabetes, glucagon-like peptide-1 (GLP-1) receptor agonists and in

172 Glucagon-like peptide-1 (GLP-1) receptor agonists and so

173 Glucagon-like peptide-1 (GLP-1) receptor agonists are ef

174 Glucagon-like peptide-1 (GLP-1) receptor agonists are ef

175 Dulaglutide and liraglutide, both glucagon-like peptide-1 (GLP-1) receptor agonists, impro

176 olgus monkeys dosed with two different human glucagon-like peptide-1 (GLP-1) receptor agonists.

177 amine-norepinephrine reuptake inhibitor, and glucagon-like peptide-1 (GLP-1) receptor agonists.

178 The glucagon-like peptide-1 (GLP-1) receptor and the glucose

179 The glucagon-like peptide-1 (GLP-1) receptors are important

180 Recent evidence indicates that activation of glucagon-like peptide-1 (GLP-1) receptors in the ventral

181 The glucagon and glucagon-like peptide-1 (GLP-1) receptors play important

182 oid these systemic effects while stimulating glucagon-like peptide-1 (GLP-1) secreting enteroendocrin

183 021 to be an especially potent stimulator of glucagon-like peptide-1 (GLP-1) secretion in vitro.

184 Glucagon-like peptide-1 (GLP-1) seems to mediate the met

185 Glucagon-like peptide-1 (GLP-1) signaling through the gl

186 Alhough the glucagon-like peptide-1 (GLP-1) system is critical to en

187 an 11-residue analogue of the N-terminus of glucagon-like peptide-1 (GLP-1) to investigate effects o

188 pendent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) were measured.

189 ecystokinin (CCK); peptide YY3-36 (PYY3-36); glucagon-like peptide-1 (GLP-1)) excite vagal afferent n

190 , we use the validated diabetes therapeutic, glucagon-like peptide-1 (GLP-1), and the target of clini

191 hormones, such as cholecystokinin (CCK) and glucagon-like peptide-1 (GLP-1), are released following

192 -dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), cholecystokinin (CCK) a

193 We measured tastant-dependent secretion of glucagon-like peptide-1 (GLP-1), glucagon, and neuropept

194 lucose, plasma insulin, C-peptide, glucagon, glucagon-like peptide-1 (GLP-1), glucose-dependent insul

195 bolically-related peptide hormone receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insul

196 lowering effects of a gut-released hormone, glucagon-like peptide-1 (GLP-1), has been reported in th

197 pendent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), is unknown.

198 Protein increased dose-dependently glucagon-like peptide-1 (GLP-1), peptide YY (PYY) 3-36,

199 lation of an important pharmaceutical, human glucagon-like peptide-1 (GLP-1).

200 ne (gcg), which encodes the incretin hormone glucagon-like peptide-1 (GLP-1).

201 ch in turn is critical for the production of glucagon-like peptide-1 (GLP-1).

202 Currently, only glucagon-like peptide-1 (GLP1) analogs are able to achie

203 together with the beneficial effects of the glucagon-like peptide-1 agonist exendin-4 in transgenic

204 odium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 agonists, and suggest how such d

205 Weight-neutral treatment with a glucagon-like peptide-1 analog activates several cardiop

206 vestigate the neuroprotective effects of the glucagon-like peptide-1 analog exenatide in resuscitated

207 Here we examine the cardiac effects of the glucagon-like peptide-1 analog liraglutide in a model of

208 ation of beta-cells with an incretin hormone glucagon-like peptide-1 analog or with a fatty acid rece

209 Glucagon-like peptide-1 analogs are approved for type 2

210 These data support a role for glucagon-like peptide-1 analogs in limiting the cardiova

211 trophy mice and further demonstrate that the glucagon-like peptide-1 analogue exendin-4, a well-toler

212 Liraglutide, a glucagon-like peptide-1 analogue, has been shown to have

213 f target engagement for clinical trials with glucagon-like peptide-1 analogues in multiple system atr

214 rolonging the half-life of incretins such as glucagon-like peptide-1 and gastric inhibitory peptide,

215 ysiological effects of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypepti

216 ieved, not all participants had increases in glucagon-like peptide-1 and gastrin concentrations that

217 ates Ca(2+) , cAMP, and insulin responses to glucagon-like peptide-1 and its metabolites following il

218 L-cells, better known for their secretion of glucagon-like peptide-1 and peptideYY.

219 ood glucose coefficient of variation for the glucagon-like peptide-1 and saline groups was 18.0% +/-

220 The glucagon-like peptide-1 cohort (n = 9) and saline cohort

221 ood glucose ranged from 7.2% to 30.4% in the glucagon-like peptide-1 group and from 19.8% to 56.8% in

222 Blood glucose levels in the glucagon-like peptide-1 group were better controlled wit

223 mmol/L) in both groups were low (one in the glucagon-like peptide-1 group, three in the saline group

224 n of a long-acting analog of the gut-hormone glucagon-like peptide-1 highlights the therapeutic poten

225 ced and density of endocrine cells secreting glucagon-like peptide-1 increased.

226 eceptor activation, whereas responses to the glucagon-like peptide-1 or the glucagon-like peptide-1 r

227 Glucagon-like peptide-1 receptor (GLP-1R) activation in

228 Central glucagon-like peptide-1 receptor (GLP-1R) activation red

229 ffects of LiCl appear to be mediated through glucagon-like peptide-1 receptor (GLP-1R) activation, we

230 Here we hypothesize that manipulating glucagon-like peptide-1 receptor (GLP-1R) activity selec

231 Exendin-4 (Ex4), a glucagon-like peptide-1 receptor (GLP-1R) agonist approv

232 ble incretin mimetic based upon the specific glucagon-like peptide-1 receptor (GLP-1R) agonist liragl

233 Glucagon-like peptide-1 receptor (GLP-1R) agonists and d

234 As the anorectic effects of glucagon-like peptide-1 receptor (GLP-1R) agonists are p

235 Glucagon-like peptide-1 receptor (GLP-1R) agonists reduc

236 The glucagon-like peptide-1 receptor (GLP-1R) and the glucag

237 Therapeutic intervention to activate the glucagon-like peptide-1 receptor (GLP-1R) enhances gluco

238 We have shown previously that the incretin glucagon-like peptide-1 receptor (GLP-1R) internalizes f

239 The glucagon-like peptide-1 receptor (GLP-1R) is a key thera

240 The glucagon-like peptide-1 receptor (GLP-1R) is a major the

241 The glucagon-like peptide-1 receptor (GLP-1R) is expressed i

242 first orally bioavailable and CNS penetrant glucagon-like peptide-1 receptor (GLP-1R) noncompetitive

243 tivated positive allosteric modulator of the glucagon-like peptide-1 receptor (GLP-1R), a class B GPC

244 f intraduodenal metformin, and both duodenal glucagon-like peptide-1 receptor (Glp-1r)-protein kinase

245 hibits food-motivated behaviors through vCA1 glucagon-like peptide-1 receptor (GLP-1R).

246 mpare the efficacy and safety of long-acting glucagon-like peptide-1 receptor agonist dulaglutide wit

247 ponses to the glucagon-like peptide-1 or the glucagon-like peptide-1 receptor agonist exendin-4 were

248 smotic pump to give continuous delivery of a glucagon-like peptide-1 receptor agonist for 6-12 months

249 To determine the effects of the glucagon-like peptide-1 receptor agonist liraglutide add

250 Albiglutide is a glucagon-like peptide-1 receptor agonist, a new class of

251 ons in the dipeptidyl peptidase-4 inhibitor, glucagon-like peptide-1 receptor agonist, and sodium-glu

252 Once-weekly glucagon-like peptide-1 receptor agonists (GLP-1RAs) are

253 Both glucagon-like peptide-1 receptor agonists and dipeptidyl

254 Glucagon-like peptide-1 receptor agonists exenatide and

255 More recently, the glucagon-like peptide-1 receptor agonists liraglutide an

256 Glucagon-like peptide-1 receptor agonists may have addit

257 f dipeptidyl peptidase-4 inhibitors and some glucagon-like peptide-1 receptor agonists, at least in t

258 We assessed two glucagon-like peptide-1 receptor agonists, once-weekly a

259 CT in combination with CT (SPECT/CT) with a glucagon-like peptide-1 receptor avid radiotracer, and c

260 in vivo We further demonstrate that an ileal glucagon-like peptide-1 receptor-dependent neuronal netw

261 with exceptional selectivity over the human glucagon-like peptide-1 receptor.

262 Given that PVT neurons express glucagon-like peptide-1 receptors (GLP-1R), which are cr

263 for small non-peptide molecules to activate glucagon-like peptide-1 receptors.

264 ly reported for LCFAs, including stimulating glucagon-like peptide-1 secretion from enteroendocrine c

265 that the addition of continuous infusion of glucagon-like peptide-1 to intensive insulin therapy wou

266 rs in hippocampal neurons to reduce (leptin, glucagon-like peptide-1) or increase (ghrelin) food inta

267 This system consists of glucagon-like peptide-1, a type-2 diabetes drug fused to

268 by fusion of protease cleavable oligomers of glucagon-like peptide-1, a type-2 diabetes drug, and a t

269 e developed that were transfected to produce glucagon-like peptide-1, an incretin hormone with known

270 entrations of total ghrelin, peptide YY, and glucagon-like peptide-1, leptin, adiponectin, expired 13

271 The incretin hormone, glucagon-like peptide-1, promotes myocardial glucose upt

272 Glucagon-like peptide-1-based (GLP-1-based) therapies im

273 lunted the body weight-lowering effects of a glucagon-like peptide-1-estrogen (GLP-1-estrogen) conjug

274 Administration of a recently developed glucagon-like peptide-1-estrogen (GLP-1-estrogen) conjug

275 changes in glucose, insulin, peptide YY, and glucagon-like peptide-1.

276 , we investigated the effects of G49, a dual glucagon-like peptide-1/glucagon receptor agonist, on NA

277 Dual-acting glucagon-like peptide-1/glucagon receptor agonists such

278 haracterization, and clinical development of glucagon-like-peptide-1 (GLP-1) spans more than 30 years

279 Postprandial glucagon-like peptide 17-36 (P = 0.784) and insulin (P =

280 the first highly selective and CNS penetrant glucagon-like peptide-1R (GLP-1R) positive allosteric mo

281 (PYY), glucagon-like peptide 1 (GLP-1), and glucagon-like peptide 2 (GLP-2) concentrations was great

282 GLM led to a decline in circulating glucagon-like peptide 2 (GLP-2) during TPN.

283 The gut hormone glucagon-like peptide-2 (GLP-2) facilitates intestinal a

284 Glucagon-like peptide-2 (GLP-2) is a 33-amino-acid progl

285 Glucagon-like peptide-2 receptor agonists have therapeut

286 Here I provide an overview of the actions of glucagon-like peptide (GLP)-1 and GLP-2, the two major e

287 ABSTACT: The gut hormone glucagon-like peptide (GLP)-1 and its analogues represen

288 IL6 increases production of glucagon-like peptide (GLP)-1 by L cells and alpha cells

289 nts the inactivation of the incretin hormone glucagon-like peptide (GLP)-1 in the peripheral circulat

290 Hypoglycemia can be avoided with glucagon-like peptide (GLP)-1 receptor agonists, which a

291 FFA3 colocalised with glucagon-like peptide (GLP)-1, whereas FFA2 colocalised

292 stimulates duodenal HCO3(-) secretion via a glucagon-like peptide (GLP)-2 pathway, whereas FFA2 acti

293 Teduglutide, a recombinant analog of human glucagon-like peptide (GLP)-2, is a novel therapy recent

294 Growing evidence suggests that agonists of glucagon-like peptide (GLP-1) receptor exert neuroprotec

295 r suggested the presence of the gut hormone, glucagon-like peptide (GLP-1), in deep short axon cells

296 dase (DPP4i), which prevents the cleavage of glucagon-like peptide (GLP-1), to adult RIPCreER-EYFP mi

297 e effect of diacetyl on the satiety hormone, glucagon-like peptide (GLP-1), using the enteroendocrine

298 as follows: glucagon in the alpha cells and glucagon-like peptides (GLP)-1 and -2 in the L cells and

299 The glucagon-like peptides (GLP-1 and GLP-2) are processed f

300 ncretin-based, antidiabetes therapies (i.e., glucagon-like peptide [GLP]-1 receptor agonists and dipe